<var id="thfl3"></var>
<var id="thfl3"></var>
<var id="thfl3"><video id="thfl3"><thead id="thfl3"></thead></video></var><menuitem id="thfl3"></menuitem>
<var id="thfl3"></var><cite id="thfl3"></cite><var id="thfl3"><video id="thfl3"></video></var>
<var id="thfl3"><span id="thfl3"></span></var><cite id="thfl3"><span id="thfl3"><var id="thfl3"></var></span></cite>
<ins id="thfl3"><span id="thfl3"><menuitem id="thfl3"></menuitem></span></ins>
<var id="thfl3"></var>

Patients and consumers

The European Medicines Agency (EMA) and patients have been actively interacting since the creation of the Agency in 1995. This cooperation was extended to include consumer groups with an interest in medicines. Both of these stakeholder groups bring a 'real-life' experience as well as specific knowledge and expertise to scientific discussions on medicines and on the impact of regulatory decisions. Collaborating with these groups supports transparency and improves regulatory processes.

PDF icon Download image in PDF format

Framework for interaction

The framework for interaction between EMA and patients and consumers and their organisations outlines the basis for involving patients and consumers in Agency activities. EMA's Management Board endorsed a revised framework in 2014:

The framework aims at:

  • supporting the Agency to access experiences of diseases, their management and information on current use of medicines;
  • contributing to more efficient and targeted communication to patients and consumers;
  • enhancing understanding of the role of the EU medicines regulatory network.

This framework is in line with EMA's overarching framework for stakeholder relations management, which the EMA Management Board adopted in June 2016:

Activities of patients and consumers

Patients and consumers are involved in a wide range of activities at the Agency, including:

Stakeholder engagement report

EMA publishes an annual report on its interactions with patients, consumers, healthcare professionals, academics and their organisations, incorporating both quantitative and qualitative data.

For previous reports, see Key documents.

Input towards revision of global clinical practice guidance

EMA is helping ICH to ensure that the perspectives of European patients, healthcare professionals and clinical researchers are taken into account in the ongoing revision of its?International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) E6 good clinical practice (GCP) guideline, by coordinating the stakeholder engagement process in Europe on the behalf of ICH.

As a first step, EMA?held?a workshop?with its Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) Working Parties in June 2020?to gather their views and experiences. The workshop summary report is available:

ICH is revising this guideline to make it more responsive to advances in clinical trial design and conduct. It has committed itself to engaging stakeholders from the outset of the revision process, particularly patient representatives and academic clinical researchers. This is to ensure that the revised guideline will meet?the needs of those conducting or participating in clinical trials.

More information on the?ICH E6 revision process is available on .


How useful was this page?

Add your rating
3 ratings
1 rating
3 ratings
1 rating
欧美大屁股XXXX,免费1级做爰片L在线观看,在线观看国产高清免费不卡,a 成 人小说网站在线观看